Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 61 of 114, showing 5 Applications out of 567 total, starting on record 301, ending on 305

# Protocol No Study Title Investigator(s) & Site(s)

301.

ECCT/24/02/09   pionERA
    This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of   giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor   (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal   growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant   endocrine therapy.   
Principal Investigator(s)
1. Dr Sitna Ali
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
View

302.

ECCT/21/07/02   TALIOS
    A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS WITH ADVANCED OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
View

303.

ECCT/25/11/06   MK-8527-011 Study
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis   
Principal Investigator(s)
1. Dr Maricianah Onono
Site(s) in Kenya
1. Nyanza Reproductive Health Society (NRHS), UNIM Research and Training Centre (URTC) (Kisumu county)
2. Kenya Impact Research and Development Organization (K-IRDO) (Kisumu county)
3. Partners for Health and Development in Africa – Sex workers Outreach Program (PHDA – SWOP) Clinic- Nairobi, Kenya (Nairobi City county)
 
View

304.

ECCT/25/11/07   MK-8527 as HIV-1 PrEP
    Protocol Title: A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis   
Principal Investigator(s)
1. John Mark Ayallo
2. Kelvin Jerry Wandera
3. John Okanda
4. Joash Diemo
5. Tobias Odwar
6. Jacob Onyango
Site(s) in Kenya
1. Kenya Impact Research and Development Organization (K-IRDO) (Kisumu county)
2. Nyanza Reproductive Health Society (NRHS), UNIM Research and Training Center (URTC) (Kisumu county)
3. Partners for Health and Development in Africa – Sex workers Outreach Program (PHDA – SWOP) (Nairobi City county)
 
View

305.

ECCT/25/11/05   MK-8527-011 Study
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis   
Principal Investigator(s)
1. Dr. Joshua Kimani
Site(s) in Kenya
1. Nyanza Reproductive Health Society (NRHS), UNIM Research and Training Centre (URTC) (Kisumu county)
2. Partners for Health and Development in Africa – Sex workers Outreach Program (PHDA – SWOP) Clinic- Nairobi, Kenya (Nairobi City county)
3. Kenya Impact Research and Development Organization (K-IRDO) (Kisumu county)
 
View